Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial

Cited by (1,001)

Items 201–300 of 1,001

1. Evaluation of humoral and cellular response to four vaccines against COVID-19 in different age groups: A longitudinal study
   Giorgio Fedele, Filippo Trentini, Ilaria Schiavoni, Sergio Abrignani, Guido Antonelli, Vincenzo Baldo, Tatjana Baldovin, Alessandra Bandera, Filippa Bonura, Pierangelo Clerici et al. · 2022 · Frontiers in Immunology
2. Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers
   Pete Schmidt, Kristin M. Narayan, Yong Li, Chengzi I. Kaku, Michael E. Brown, Elizabeth R. Champney, James C. Geoghegan, Maximiliano Vásquez, Eric M. Krauland, Thomas J. Yockachonis et al. · 2023 · Science Translational Medicine
3. SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders
   José Luís Piñana, Lucía López‐Corral, Rodrigo Martino, Lourdes Vázquez, Ariadna Pérez, Gabriel Martin‐Martin, Beatriz Gago, Gabriela Sanz‐Linares, Andrés Sánchez‐Salinas, Lucı́a Villalón et al. · 2022 · Journal of Hematology & Oncology
4. The quest for vaccine-induced immune correlates of protection against tuberculosis
   Elisa Nemes, Andrew J. Fiore-Gartland, César Boggiano, Margherita Coccia, Patricia D’Souza, Peter B. Gilbert, Ann M. Ginsberg, Ollivier Hyrien, Dominick J. Laddy, Karen W. Makar et al. · 2022 · Vaccine Insights
5. Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases
   Lindsey Robert Baden, Hana M. El Sahly, Brandon J. Essink, Dean A. Follmann, Greg Hachigian, Cynthia Becher Strout, J. Scott Overcash, Susanne Doblecki‐Lewis, Jennifer A. Whitaker, Evan J. Anderson et al. · 2024 · Nature Communications
6. Learning through a Pandemic: The Current State of Knowledge on COVID-19 and Cancer
   Arielle Elkrief, Julie Tsu-Yu Wu, Chinmay Jani, Kyle T. Enriquez, Michael J. Glover, Mansi R. Shah, Hira Ghazal Shaikh, Alicia C. Beeghly-Fadiel, Benjamin C. French, Sachin R. Jhawar et al. · 2021 · Cancer Discovery
7. Metabolite, protein, and tissue dysfunction associated with COVID-19 disease severity
   Ali Rahnavard, Brendan T. Mann, Abhigya Giri, Ranojoy Chatterjee, Keith A. Crandall · 2022 · Scientific Reports
8. Boosting immunity to Omicron
   Xiaoying Shen · 2022 · Nature Medicine
9. Understanding Anti-COVID-19 Vaccination Protest Slogans in the US
   Tim Futing Liao · 2022 · Frontiers in Communication
10. Natural and hybrid immunity following four COVID-19 waves: A prospective cohort study of mothers in South Africa
    Heather Joy Zar, Rae P. MacGinty, Lesley Workman, Maresa Botha, Marina Johnson, Adam Hunt, Tiffany Burd, Mark Patrick Nicol, Stefan Flasche, Billy J. Quilty et al. · 2022 · EClinicalMedicine
11. An mRNA-based seasonal influenza vaccine in adults: Results of two phase 3 randomized clinical trials and correlate of protection analysis of hemagglutination inhibition titers
    Boris Kandinov, Mieke Soens, Wenmei Huang, Conrado Juan Llapur, David J. Ensz, Brandon J. Essink, Carlos A. Fierro, Jignesh Vakil, Alicia Pucci, Jia Guo et al. · 2025 · Human Vaccines & Immunotherapeutics
12. An evaluation of the safety and immunogenicity of MVC-COV1901: Results of an interim analysis of a phase III, parallel group, randomized, double-blind, active-controlled immunobridging study in Paraguay
    Julio César Torales, Osmar Cuenca-Torres, Laurentino Barrios, Luis Armoa, Gladys Estigarribia, Gabriela Sanabria, Meei‐Yun Lin, Josue Antonio Garcia Estrada, Lila Estephan, Hao‐Yuan Cheng et al. · 2022 · Vaccine
13. Correlates of protection and viral load trajectories in omicron breakthrough infections in triple vaccinated healthcare workers
    Ulrika Wimmercranz Marking, Sebastian Havervall, Nina Greilert‐Norin, Oscar Bladh, Wanda Christ, Max Gordon, Henry Ng, Kim G. Blom, Mia Phillipson, Sara M. Mangsbo et al. · 2023 · Nature Communications
14. Immunogenicity and reactogenicity of intradermal mRNA-1273 SARS-CoV-2 vaccination: a non-inferiority, randomized-controlled trial
    Margaretha L.M. Prins, Geert V.T. Roozen, Cilia R. Pothast, Wesley Huisman, Rob S. van Binnendijk, Gerco den Hartog, Vincent P. Kuiper, Corine Prins, Jacqueline J. Janse, Olivia A. C. Lamers et al. · 2024 · npj Vaccines
15. Durability of Antibody Response and Frequency of SARS-CoV-2 Infection 6 Months after COVID-19 Vaccination in Healthcare Workers
    Eric D. Laing, Carol D. Weiss, Emily C Samuels, Si’Ana A. Coggins, Wei Wang, Richard Wang, Russell A. Vassell, Spencer L. Sterling, Marana S Tso, Tonia L. Conner et al. · 2022 · Emerging infectious diseases
16. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Specific T Cells and Antibodies in Coronavirus Disease 2019 (COVID-19) Protection: A Prospective Study
    Ivan A. Molodtsov, Evgenii Kegeles, Alexander N. Mitin, Olga N. Mityaeva, Oxana E. Musatova, Anna E. Panova, Mikhail V. Pashenkov, Iuliia O. Peshkova, Almaqdad Alsalloum, Walaa Asaad et al. · 2022 · Clinical Infectious Diseases
17. Comparative analysis of human immune responses following SARS-CoV-2 vaccination with BNT162b2, mRNA-1273, or Ad26.COV2.S
    Dominique J. Barbeau, Judith M. Martin, Emily Carney, Emily Dougherty, Joshua Doyle, Terence S. Dermody, Alejandro Hoberman, John V. Williams, Marian G. Michaels, John F. Alcorn et al. · 2022 · npj Vaccines
18. Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial
    Yuemiao Zhang, Xupu Ma, Guanghong Yan, Ying Wu, Yanli Chen, Zumi Zhou, Na Wan, Wei Su, Fengwei Liu, Muxian Dai et al. · 2022 · EClinicalMedicine
19. Severe immunosuppression is related to poorer immunogenicity to SARS-CoV-2 vaccines among people living with HIV
    Anaïs Corma‐Gómez, Marta Fernández‐Fuertes, Estefanía García, Ana Paula Fuentes, Cristina Gómez‐Ayerbe, Antonio Rivero‐Juárez, Carmen Baxin Domínguez, Marta Santos, Laura Viñuela, Rosario Palacios et al. · 2022 · Clinical Microbiology and Infection
20. Protection against SARS-CoV-2 Omicron BA.4/5 variant following booster vaccination or breakthrough infection in the UK
    Jia Wei, Philippa Clare Matthews, Nicole E Stoesser, John N Newton, Ian D. Diamond, Ruth Studley, Nick P. Taylor, John I. Bell, Jeremy Farrar, Jaison B. Kolenchery et al. · 2023 · Nature Communications
21. Population homogeneity for the antibody response to COVID-19 BNT162b2/Comirnaty vaccine is only reached after the second dose across all adult age ranges
    João Faro Viana, Marie‐Louise Bergman, Lígia Antunes Gonçalves, Nádia Duarte, Teresa Penha Coutinho, Patrícia Borges, Christian Diwo, Rute Castro, Paula Matoso, Vanessa Malheiro et al. · 2022 · Nature Communications
22. IgG Anti-Spike Antibodies and Surrogate Neutralizing Antibody Levels Decline Faster 3 to 10 Months After BNT162b2 Vaccination Than After SARS-CoV-2 Infection in Healthcare Workers
    Bram Decru, Jan Van Elslande, Sophie Steels, Gijs Van Pottelbergh, Lode Godderis, Bram Van Holm, Xavier Bossuyt, Johan Van Weyenbergh, Piet Maes, Pieter Vermeersch · 2022 · Frontiers in Immunology
23. Reduced immunogenicity of BNT162b2 booster vaccination in combination with a tetravalent influenza vaccination: results of a prospective cohort study in 838 health workers
    Helga Radner, Daniela Sieghart, Anselm Jorda, Clemens Fedrizzi, Timothy Hasenoehrl, Andrej Zdravkovic, Monika Redlberger‐Fritz, Elisabeth Puchammer-Stoeckl, Karolina Anderle, Felix Bergmann et al. · 2022 · Clinical Microbiology and Infection
24. Prior SARS-CoV-2 infection enhances and reshapes spike protein–specific memory induced by vaccination
    Véronique Barateau, Loïc Peyrot, Carla Saade, Bruno Pozzetto, Karen Brengel‐Pesce, Mad‐Hélénie Elsensohn, Omran Allatif, Nicolas Guibert, Christelle Compagnon, Natacha Mariano et al. · 2023 · Science Translational Medicine
25. Vaccine effectiveness against onward transmission of SARS-CoV2-infection by variant of concern and time since vaccination, Belgian contact tracing, 2021
    Toon Braeye, Lucy Catteau, Ruben Brondeel, Joris Adriaan Frank van Loenhout, Kristiaan Proesmans, Laura Cornelissen, Herman J. Van Oyen, Veerle Stouten, Pierre Hubin, Matthieu Billuart et al. · 2022 · Vaccine
26. SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination
    José Luís Piñana, Rodrigo Martino, Lourdes Vázquez, Lucía López‐Corral, Ariadna Pérez, Pedro Chorão, Alejandro Avendaño, María‐Jesús Pascual, Andrés Sánchez‐Salinas, Gabriela Sanz‐Linares et al. · 2023 · Bone Marrow Transplantation
27. Kinetics of the SARS-CoV-2 Antibody Avidity Response Following Infection and Vaccination
    Laura García, Tom Woudenberg, Jason Rosado, Adam H. Dyer, Françoise Donnadieu, Delphine Planas, Timothée Bruel, Olivier Schwartz, Thiérry Prazuck, Aurélie Velay et al. · 2022 · Viruses
28. ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19
    Paulina Kapłonek, Deniz Cizmeci, Gaurav Kwatra, Alane Izu, Jessica Shih-Lu Lee, Harry L. Bertera, Stephanie Fischinger, Colin J. Mann, Fatima Amanat, Wenjun Wang et al. · 2023 · Nature Immunology
29. Serologic response and safety of COVID-19 vaccination in HSCT or CAR T-cell recipients: a systematic review and meta-analysis
    Chenghao Ge, Kelei Du, Mingjie Luo, Kaini Shen, Yangzhong Zhou, Kaiyuan Guo, Yang Liu, Chen Yin, Yi Li, Guanqiao Li et al. · 2022 · Experimental Hematology and Oncology
30. Predictors of long-term neutralizing antibody titers following COVID-19 vaccination by three vaccine types: the BOOST study
    Aric A. Prather, Ethan G. Dutcher, James E. Robinson, Jue Lin, Elizabeth Helen Blackburn, Frederick M. Hecht, Ashley E. Mason, Elena Fromer, Bresh Merino, Remi Frazier et al. · 2023 · Scientific Reports
31. Efficacy and limitations of SARS-CoV-2 vaccines - A systematic review
    Muhammad Azeem, Patrizia Cancemi, Farwa Mukhtar, Sefora Marino, Emanuela Peri, Giulia Di Prima, Viviana De · 2025 · Life Sciences
32. One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients
    José Luís Piñana, Lourdes Vázquez, Marisa Calabuig, Lucía López‐Corral, Gabriel Martin‐Martin, Lucı́a Villalón, Gabriela Sanz‐Linares, Venancio Conesa, Andrés Sánchez‐Salinas, Beatriz Gago et al. · 2023 · Blood Cancer Journal
33. Effect of Systemic Lupus Erythematosus and Immunosuppressive Agents on COVID ‐19 Vaccination Antibody Response
    Michelle Petri, Daniel P. Joyce, Kristin Haag, Andrea Fava, DANIEL W. GOLDMAN, Diana Zhong, Shaoming Xiao, Aaron Michael Milstone, Laurence S. Magder · 2023 · Arthritis Care & Research
34. Hybrid immunity expands the functional humoral footprint of both mRNA and vector-based SARS-CoV-2 vaccines
    Paulina Kapłonek, Yixiang Deng, Jessica Shih-Lu Lee, Heather Joy Zar, Dace Zavadska, Marina Johnson, Douglas A. Lauffenburger, David Goldblatt, Galit Alter · 2023 · Cell Reports Medicine
35. Rapid Decline in Vaccine-Boosted Neutralizing Antibodies Against SARS-CoV-2 Omicron Variant
    Kirsten E. Lyke, Robert L. Atmar, Clara P. Dominguez Islas, Christine M. Posavad, Daniel W. Szydlo, Rahul PaulChourdhury, Meagan E. Deming, Amanda Eaton, Lisa A. Jackson, Angela Ramon Branche et al. · 2022 · SSRN Electronic Journal
36. Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial
    Carl S. Goodyear, Amit K. Patel, Eleanor J. Barnes, Michelle Kay Willicombe, Stefan Siebert, Thushan I. de Silva, John Andrew Snowden, Sean H. Lim, Sarah Jane Bowden, Lucinda Jane Billingham et al. · 2024 · The Lancet Rheumatology
37. A cocktail nanovaccine targeting key entry glycoproteins elicits high neutralizing antibody levels against EBV infection
    Ling Zhong, Wanlin Zhang, Hong Liu, Xinyu Zhang, Zeyu Yang, Zhenfu Wen, Ling Chen, Haolin Chen, Yanran Luo, Yanhong Chen et al. · 2024 · Nature Communications
38. Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection
    Edwards Pradenas, Benjamin Trinité, Víctor Urrea, Sílvia Marfil, Ferran Tarrés-Freixas, Raquel Ortiz, Carla Rovirosa, Jordi Rodon, Júlia Vergara‐Alert, Joaquím Segalés et al. · 2022 · Cell Reports Medicine
39. Enhanced Humoral Immune Response After COVID-19 Vaccination in Elderly Kidney Transplant Recipients on Everolimus Versus Mycophenolate Mofetil–containing Immunosuppressive Regimens
    Silke E. de Boer, Stefan P. Berger, Coretta van Leer‐Buter, Bart‐Jan Kroesen, Debbie van Baarle, Jan‐Stephan Sanders, on behalf of the OPTIMIZE study group · 2022 · Transplantation
40. Comparison of Levels of Nasal, Salivary, and Plasma Antibody to Severe Acute Respiratory Syndrome Coronavirus 2 During Natural Infection and After Vaccination
    Jeffrey I. Cohen, Lesia K. Dropulic, Kening Wang, Krista Gangler, Kayla Morgan, Kelly Liepshutz, Tammy A. Krogmann, Mir A. Ali, Jing Qin, Jing Wang et al. · 2022 · Clinical Infectious Diseases
41. Antibody persistence and safety after heterologous boosting with orally aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously: 12-month analyses of a randomized controlled trial
    Lairun Jin, Rong Tang, Shipo Wu, Xiling Guo, Haitao Huang, Lihua Hou, Xiaoqin Chen, Tao Zhu, Jin-Bo Gou, Jin Zhong et al. · 2022 · Emerging Microbes & Infections
42. Tracking immune correlates of protection for emerging SARS-CoV-2 variants
    Eric James Nilles, Cecilia Then Paulino, Michael de St. Aubin, William Duke, Petr Jarolı́m, Isaac Miguel Sánchez, Kristy O. Murray, Colleen L. Lau, Emily Zielinski Gutiérrez, Ronald Skewes-Ramm et al. · 2023 · The Lancet Infectious Diseases
43. Maternal COVID-19 Vaccination and Prevention of Symptomatic Infection in Infants
    Cristina V. Cardemil, Yi Cao, Christine M. Posavad, Martina L. Badell, Katherine E. Bunge, Mark J. Mulligan, Lalitha Parameswaran, Courtney Olson‐Chen, Richard M. Novak, Rebecca C. Brady et al. · 2024 · PEDIATRICS
44. Immune correlates analysis of mRNA-1345 RSV vaccine efficacy clinical trial
    Chong Ma, Jiejun Du, Lan Lan, Archana Kapoor, Gonzalo Pérez Marc, Gilberto Jimenez, Christopher James Arthur Duncan, Nancy Le Cam, Nina Lin, Frances H. Priddy et al. · 2025 · Nature Communications
45. Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases: consensus statements from the ERA-IWG and EUVAS
    Kate Stevens, Eleni A. Frangou, Jae Il Shin, Hans‐Joachim Anders, Annette N. Bruchfeld, Ulf Schönermarck, Thomas Hauser, Kerstin W A Westman, Gema Maria Fernandez Juarez, Jürgen Floege et al. · 2022 · Nephrology Dialysis Transplantation
46. Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines
    Lu Lu, Lin‐Lei Chen, Ruiqi Zhang, Owen Tak‐Yin Tsang, Jacky Man‐Chun Chan, Anthony Raymond Tam, Wai-Shing Leung, Thomas Shiu‐Hong Chik, Daphne Pui-Ling Lau, Chris Yau-Chung Choi et al. · 2022 · EBioMedicine
47. Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy
    Silje Watterdal Syversen, Ingrid Jyssum, Anne Therese Tveter, Joe Sexton, Ingrid Egeland Christensen, Trung The Tran, K. H. Bjørlykke, Siri Mjaaland, David John Warren, Tore Kristian Kvien et al. · 2022 · RMD Open
48. National seroepidemiological study of COVID‐19 after the initial rollout of vaccines: Before and at the peak of the Omicron‐dominant period in Japan
    Takeshi Arashiro, Satoru Arai, Ryo Kinoshita, Kanako Otani, Shô Miyamoto, Daisuke Yoneoka, Taro Kamigaki, Hiromizu Takahashi, Hiromi Hibino, Mai Okuyama et al. · 2023 · Influenza and Other Respiratory Viruses
49. SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary Analyses
    Angela Ramon Branche, Nadine Rouphael, David Joseph Diemert, Ann Regina Falsey, Cecilia Losada, Lindsey Robert Baden, Sharon E. Frey, Jennifer A. Whitaker, Susan J. Little, Evan J. Anderson et al. · 2022 · medRxiv
50. Humoral and Cellular Responses to COVID-19 Vaccination Indicate the Need for Post-Vaccination Testing in Frail Population
    Wojciech Witkowski, Sarah Gerlo, Evelien De Smet, Magdalena Wejda, Delphine Diana Acar, Steven F. J. Callens, Stefan Heytens, Elizaveta Y. Padalko, Hanne Vercruysse, Piet Cools et al. · 2022 · Vaccines
51. Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trial
    Astha Thakkar, Kith Pradhan, Benjamin Duva, Juan Manuel Carreño, Srabani Sahu, Victor J. Thiruthuvanathan, Sean Campbell, Sonia Gallego, Tushar Damodar Bhagat, Johanna Rivera et al. · 2023 · eLife
52. IL-10 suppresses T cell expansion while promoting tissue-resident memory cell formation during SARS-CoV-2 infection in rhesus macaques
    Christine E Nelson, Taylor W. Foreman, Eduardo R. Fukutani, Keith D. Kauffman, Shunsuke Sakai, Joel D. Fleegle, Felipe Gomez, NIAID/DIR Tuberculosis Imaging Program, Sydnee T. Gould, Cyril Le Nouën et al. · 2024 · PLoS Pathogens
53. Safety, tolerability, viral kinetics, and immune correlates of protection in healthy, seropositive UK adults inoculated with SARS-CoV-2: a single-centre, open-label, phase 1 controlled human infection study
    Susan Jackson, Julia L. Marshall, Andrew Mawer, Raquel Lopez Ramon, Stephanie A. Harris, Iman Satti, Eileen Hughes, Hannah Preston-Jones, Ingrid Cabrera Puig, Stéphanie Longet et al. · 2024 · The Lancet Microbe
54. Repeated COVID-19 mRNA-based vaccination contributes to SARS-CoV-2 neutralizing antibody responses in the mucosa
    Jozefien Declercq, Sarah Gerlo, Sharon Van Nevel, Natalie De Ruyck, Gabriële Holtappels, Liesbeth M. Delesie, Els Tobback, Inés Lammens, Nikita Gerebtsov, Koen Sedeyn et al. · 2024 · Science Translational Medicine
55. Designed mosaic nanoparticles enhance cross-reactive immune responses in mice
    Eric Ji Da Wang, Alexander A. Cohen, Luis F. Caldera, Jennifer R. Keeffe, Annie V. Rorick, Yusuf M Adia, Priyanthi N.P. Gnanapragasam, Pamela J. Björkman, Arup K. Chakraborty · 2025 · Cell
56. Humoral and cellular immune responses to the SARS‐CoV‐2 BNT162b2 vaccine among a cohort of solid organ transplant recipients and healthy controls
    Ahmad Yanis, Zaid Haddadin, Andrew J. Spieker, Danya Waqfi, Danielle A. Rankin, Rana Talj, Lora D. Thomas, Kelly A. Birdwell, Lauren J Ezzell, Marcia A. Blair et al. · 2021 · Transplant Infectious Disease
57. Differential Dynamics of SARS-CoV-2 Binding and Functional Antibodies upon BNT162b2 Vaccine: A 6-Month Follow-Up
    Giulia Matusali, Giuseppe Sberna, Silvia Meschi, Giulia Gramigna, Francesca Colavita, Daniele Lapa, Massimo Francalancia, Aurora Bettini, Maria Rosaria Capobianchi, Vincenzo Puro et al. · 2022 · Viruses
58. COVID-19 breakthrough infections and humoral immune response among BNT162b2 vaccinated healthcare workers in Malaysia
    Su Lan Yang, Adiratna Mat Ripen, Chin Tho Leong, Jen Ven Lee, Chia How Yen, Avinash Kumar Chand, Karina Koh, Nur Aisyah Binti Abdul Rahim, Varaalakshmy Gokilavanan, Nik Nur Eliza Mohamed et al. · 2022 · Emerging Microbes & Infections
59. Impact of SARS‐CoV‐2 infection on vaccine‐induced immune responses over time
    Sebastian Havervall, Ulrika Wimmercranz Marking, Nina Greilert‐Norin, Max Gordon, Henry Ng, Wanda Christ, Mia Phillipson, Peter Nilsson, Sophia Hober, Kim G. Blom et al. · 2022 · Clinical & Translational Immunology
60. Prediction of long-term kinetics of vaccine-elicited neutralizing antibody and time-varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint
    Xinhua Chen, Wei Wang, Xinghui Chen, Qianhui Wu, Ruijia Sun, Shijia Ge, Nan Zheng, Wanying Lu, Juan Yang, Lance Everett Rodewald et al. · 2022 · BMC Medicine
61. Persistent Maintenance of Intermediate Memory B Cells Following SARS-CoV-2 Infection and Vaccination Recall Response
    Jernej Pušnik, Julia König, Karola Mai, Enrico Richter, Jasmin Zorn, Hannah Proksch, Bianca Schulte, Galit Alter, Hendrik Streeck · 2022 · Journal of Virology
62. Comparison of the measured values of quantitative SARS-CoV-2 spike antibody assays
    Lars Müller, Judith Kannenberg, Ronald Biemann, Mario Hönemann, G Ackermann, Christian Jassoy · 2022 · Journal of Clinical Virology
63. Potent high-avidity neutralizing antibodies and T cell responses after COVID-19 vaccination in individuals with B cell lymphoma and multiple myeloma
    Andrea Keppler‐Hafkemeyer, Christine Greil, Paul R. Wratil, Khalid Shoumariyeh, Marcel Stern, Annika Hafkemeyer, Driti Ashok, Alexandra Hollaus, Gaia Lupoli, Alina Priller et al. · 2022 · Nature Cancer
64. Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma
    Julia Erin Wiedmeier, Madiha Iqbal, Allison Claire Rosenthal, Evandro D. Bezerra, Juan Esteban García-Robledo, Radhika Bansal, Patrick B. Johnston, Matthew A. Hathcock, Jeremy Todd Larsen, Peter Leif Bergsagel et al. · 2023 · Clinical Lymphoma Myeloma & Leukemia
65. Vaccine-induced correlate of protection against fatal COVID-19 in older and frail adults during waves of neutralization-resistant variants of concern: an observational study
    Linnea Vikström, Peter Fjällström, Yong-Dae Gwon, Daniel J. Sheward, Julia Wigren Byström, Magnus Evander, Oscar Bladh, Micael Widerström, Christian Molnár, Gunlög Rasmussen et al. · 2023 · The Lancet Regional Health - Europe
66. Tracking B cell responses to the SARS-CoV-2 mRNA-1273 vaccine
    Felipe Lopes de Assis, Kenneth B. Hoehn, Xiaozhen Zhang, Lela Kardava, Connor D. Smith, Omar El Merhebi, Clarisa M. Buckner, Krittin Trihemasava, Wei Wang, Catherine A. Seamon et al. · 2023 · Cell Reports
67. Safety and Immunogenicity of Intradermal Fractional Dose Administration of the mRNA-1273 Vaccine: A Proof-of-Concept Study
    Geert V.T. Roozen, Margaretha L.M. Prins, Rob S. van Binnendijk, Gerco den Hartog, Vincent P. Kuiper, Corine Prins, Jacqueline J. Janse, Annelieke C. Kruithof, Mariet C.W. Feltkamp, Marjan Kuijer et al. · 2022 · Annals of Internal Medicine
68. Type of vaccine and immunosuppressive therapy but not diagnosis critically influence antibody response after COVID-19 vaccination in patients with rheumatic disease
    Leonie Maria Frommert, Amanthi Nadira Arumahandi de Silva, Jan Zernicke, Veronika Scholz, Tanja Braun, Lara Maria Jeworowski, Tatjana Schwarz, Pinkus Tober‐Lau, Alexander ten Hagen, Elisa Habermann et al. · 2022 · RMD Open
69. Engineered immunogens to elicit antibodies against conserved coronavirus epitopes
    2023
70. Correlates of protection and determinants of SARS-CoV-2 breakthrough infections 1 year after third dose vaccination
    Carla Martín Pérez, Ruth Aguilar, Alfons Jiménez, Gemma Salmerón, Mar Canyelles, Rocío Rubio, Marta Vidal, Inocência Cuamba, Diana Barrios, Natalia Díaz et al. · 2024 · BMC Medicine
71. Clinical Utility of SARS-CoV-2 Serological Testing and Defining a Correlate of Protection
    Kimia Sobhani, Susan C. Cheng, Raquel A. Binder, Nicholas John Mantis, James M. Crawford, Nkemakonam C. Okoye, Jonathan G. Braun, Sandy Y. Joung, Minhao Wang, Gerard Lozanski et al. · 2023 · Vaccines
72. Age differentially impacts adaptive immune responses induced by adenoviral versus mRNA vaccines against COVID-19
    Beatrice Dallan, Davide Proietto, Martina De Laurentis, Eleonora Gallerani, Mara Martino, Sara Ghisellini, Amedeo Zurlo, Stefano Volpato, Benedetta Govoni, Michela Borghesi et al. · 2024 · Nature Aging
73. COVID-19 Vaccines
    William O. Hahn, Zanthia Wiley · 2022 · Infectious Disease Clinics of North America
74. Strong T-cell activation in response to COVID-19 vaccination in multiple sclerosis patients receiving B-cell depleting therapies
    Roberto Alfonso, Jerry Lin, Vanessa Kirschner, Joyce Lei, Grant Feuer, Michaela L. Malin, Jiayuan Liu, Morgan Roche, Saud Ahmed Sadiq · 2022 · Frontiers in Immunology
75. Anti-spike T-cell and Antibody Responses to SARS-CoV-2 mRNA Vaccines in Patients with Hematologic Malignancies
    Lee M. Greenberger, Larry A. Saltzman, Lore M. Gruenbaum, Jun Xu, Sneha T. Reddy, Jonathon W. Senefeld, Patrick W. Johnson, Paul Fields, Catherine Miller Sanders, Louis J. DeGennaro et al. · 2022 · Blood Cancer Discovery
76. Attenuated humoral responses in HIV after SARS-CoV-2 vaccination linked to B cell defects and altered immune profiles
    E. Touizer, Aljawharah Alrubayyi, R. Ford, N. Hussain, P. Gerber, Hiu-Long Shum, C. Rees-Spear, L. Muir, E. Gea-Mallorquí, J. Kopycinski et al. · 2022 · iScience
77. Long term anti-SARS-CoV-2 antibody kinetics and correlate of protection against Omicron BA.1/BA.2 infection
    Javier Perez‐Saez, María-Eugenia Zaballa, Julien Lamour, Sabine Yerly, Richard Dubos, Delphine Sophie Courvoisier, Jennifer Villers, Jean-François Balavoine, Didier Pittet, Omar Kherad et al. · 2023 · Nature Communications
78. Understanding structure activity relationships of Good HEPES lipids for lipid nanoparticle mRNA vaccine applications
    Rebecca Goldman, Namratha Turuvekere Vittala Murthy, Northen Trent, Anuranjani Balakrishnan, Sudha V. Chivukula, Hillary Danz, Timothy J. Tibbitts, Anusha Dias, Jorel Vargas, Dustin L. Cooper et al. · 2023 · Biomaterials
79. Antibody and B Cell Responses to SARS-CoV-2 Infection and Vaccination: The End of the Beginning
    Katharina Röltgen, Scott Dexter Boyd · 2023 · Annual Review of Pathology Mechanisms of Disease
80. Antibody longevity and waning following COVID-19 vaccination in a 1-year longitudinal cohort in Bangladesh
    Md. Ahsanul Haq, Anjan Kumar Roy, Razu Ahmed, Rakib Ullah Kuddusi, Monika Sinha, Md Shamim Hossain, Maya Vandenent, Mohammad Zahirul Islam, Rashid Uz Zaman, Md. Golam Kibria et al. · 2024 · Scientific Reports
81. Interpretable and Predictive Deep Neural Network Modeling of the SARS-CoV-2 Spike Protein Sequence to Predict COVID-19 Disease Severity
    Bahrad Ali Sokhansanj, Zhengqiao Zhao, GAIL L. ROSEN · 2022 · Biology
82. Combining antigenic data from public sources gives an early indication of the immune escape of emerging virus variants
    Antonia Netzl, Sina Türeli, Eric B. LeGresley, Barbara Mühlemann, Samuel Wilks, Derek J. Smith · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
83. Safety and immunogenicity of a live recombinant Newcastle disease virus-based COVID-19 vaccine (Patria) administered via the intramuscular or intranasal route: Interim results of a non-randomized open label phase I trial in Mexico
    Samuel Ponce‐de‐León, Martha Torres, Luis Enrique Soto-Ramírez, Juan José Calva, Patricio Santillán‐Doherty, Dora Eugenia Carranza-Salazar, Juan Manuel Carreño, Claudia Carranza, Esmeralda Juárez, Laura Elena Carreto-Binaghi et al. · 2022 · medRxiv
84. Neutralizing antibody correlate of protection against severe-critical COVID-19 in the ENSEMBLE single-dose Ad26.COV2.S vaccine efficacy trial
    Lindsay N. Carpp, Ollivier Hyrien, Youyi Fong, David C. Benkeser, Sanne Roels, Daniel J Stieh, Ilse Van Dromme, Griet A. Van Roey, Avi Kenny, Ying Huang et al. · 2024 · Nature Communications
85. SARS-CoV-2 antibody testing for transplant recipients: A tool to personalize protection versus COVID-19
    William A. Werbel, Dorry Lidor Segev · 2022 · American Journal of Transplantation
86. Innate and Adaptive Immune Responses in the Upper Respiratory Tract and the Infectivity of SARS-CoV-2
    Ranjan Ramasamy · 2022 · Viruses
87. Preclinical immunogenicity and efficacy of a candidate COVID-19 vaccine based on a vesicular stomatitis virus-SARS-CoV-2 chimera
    Amy S. Espeseth, Maoli Yuan, Michael P. Citron, Lucia Reiserova, Gavin Morrow, Aaron J. Wilson, Melanie S. Horton, Mark Rukhman, Keith C. Kinek, Fuxiang Hou et al. · 2022 · EBioMedicine
88. Humoral and cellular immune responses eleven months after the third dose of BNT162b2 an mRNA-based COVID-19 vaccine in people with HIV – a prospective observational cohort study
    Line Dam Heftdal, Laura Pérez‐Alós, Rasmus Bo Hasselbalch, Cecilie Bo Hansen, Sebastian Rask Hamm, Dina Leth Møller, Mia Marie Pries‐Heje, Kamille Fogh, Jan Gerstoft, Kirsten Grønbæk et al. · 2023 · EBioMedicine
89. SARS-CoV-2 and COVID-19: A Narrative Review
    Andrew D. Blann, Rebekka Heitmar · 2022 · British Journal of Biomedical Science
90. Computationally designed mRNA-launched protein nanoparticle immunogens elicit protective antibody and T cell responses in mice
    Grace G. Hendricks, Lilit Grigoryan, Mary Jane Navarro, Nicholas Catanzaro, Miranda L. Hubbard, John M. Powers, Melissa D. Mattocks, Catherine Treichel, Alexandra C. Walls, Jimin Lee et al. · 2025 · Science Translational Medicine
91. Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS‐CoV‐2 vaccination
    Moritz M. Hollstein, Lennart Münsterkötter, Michael Peter Schön, Armin Bergmann, Thea M. Husar, Anna Abratis, Abass Eidizadeh, Meike Schaffrinski, Karolin Zachmann, Änne Schmitz et al. · 2022 · Allergy
92. Severe Acute Respiratory Syndrome Coronavirus 2 Adaptive Immunity in Nursing Home Residents Following a Third Dose of the Comirnaty Coronavirus Disease 2019 Vaccine
    Estela Giménez, Eliseo Albert, João Zulaica, Ignacio Torres, Luciana Rusu, Alicia Rodríguez-Moreno, Javier S. Burgos, Salvador Peiró, Dolores Salas, Hermelinda Vanaclocha et al. · 2022 · Clinical Infectious Diseases
93. Validation and performance of a multiplex serology assay to quantify antibody responses following SARS‐CoV‐2 infection or vaccination
    Deidre E. Wilkins, Anastasia A. Aksyuk, Alexey V. Ruzin, Kevin M. Tuffy, Tina Green, Rebecca Greway, Brittany Fikes, Cyrille J. Bonhomme, Mark Thomas Esser, Elizabeth J. Kelly · 2022 · Clinical & Translational Immunology
94. mRNA booster vaccination protects aged mice against the SARS-CoV-2 Omicron variant
    Etsuro Nanishi, Marisa E. McGrath, Timothy R. O’Meara, Soumik Barman, Jingyou Yu, Huahua Wan, Carly A. Dillen, Manisha Menon, Hyuk‐Soo Seo, Kijun Song et al. · 2022 · Communications Biology
95. Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b–2a trial
    Shabir Ahmed Madhi, Gaurav Kwatra, Simone I. Richardson, Anthonet Lombard Koen, Vicky Lynne Baillie, Clare Cutland, Lee Fairlie, Sherman D. Padayachee, Keertan U.J. Dheda, Shaun Lawrence Barnabas et al. · 2022 · The Lancet Infectious Diseases
96. Evaluation of SARS‐CoV‐2 antibody levels on hospital admission as a correlate of protection against mortality
    Sylvia Mink, Wolfgang List, Guenter Hoefle, Matthias Frick, Alois Suessenbacher, Thomas L. Winder, Cornelia Fetz, Andreas Bösl, Christoph H. Saely, Heinz Drexel et al. · 2023 · Journal of Internal Medicine
97. An inactivated NDV-HXP-S COVID-19 vaccine elicits a higher proportion of neutralizing antibodies in humans than mRNA vaccination
    Juan Manuel Carreño, Ariel J. Raskin, Gagandeep Singh, Johnstone Tcheou, Hisaaki Kawabata, Charles Gleason, Komal Srivastava, Vladimir I. Vigdorovich, Nicholas Dambrauskas, Sneh Lata Gupta et al. · 2023 · Science Translational Medicine
98. Immunogenicity and protective efficacy of GBP510/AS03 vaccine against SARS-CoV-2 delta challenge in rhesus macaques
    Catherine Jacob-Dolan, Jingyou Yu, Katherine McMahan, Victoria M. Giffin, Abishek Chandrashekar, Amanda Jezek Martinot, Tochi Anioke, Olivia C. Powers, Kevin Hall, David L. Hope et al. · 2023 · npj Vaccines
99. Predictive potential of SARS-CoV-2 RNA concentration in wastewater to assess the dynamics of COVID-19 clinical outcomes and infections
    Raimundo Seguí, Rubén Cañas-Cañas, Jorge Casaña Mohedo, José Vicente Benavent-Cervera, Julio Fernández-Garrido, Raúl Juárez‐Vela, Ana Pellín-Carcelén, Vicente Gea Caballero, Vicente Andreu-Férnández · 2023 · The Science of The Total Environment
100. Safety and immunogenicity of multivalent SARS-CoV-2 protein vaccines: a randomized phase 3 trial
     Suad Hannawi, Lixin Yan, Linda Saf Eldin, Alaa Abuquta, Ahmad Alamadi, Sally Mahmoud, Aala Hassan, Miaomiao Zhang, Cuige Gao, Yuanxin Chen et al. · 2023 · EClinicalMedicine